{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:59:43Z","timestamp":1791953983366,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["569395831"],"award-info":[{"award-number":["569395831"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RA 969\/12-1"],"award-info":[{"award-number":["RA 969\/12-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116693","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:04:37Z","timestamp":1774368277000},"page":"116693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: A meta-analysis"],"prefix":"10.1016","volume":"239","author":[{"given":"Tobias","family":"Lerchner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Buehning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca I.","family":"Mincu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpaslan","family":"Tasdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Totzeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2026.116693_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ejca.2026.116693_bib2","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.ejca.2026.116693_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11897-025-00717-w","article-title":"Cardiac magnetic resonance imaging in immune checkpoint inhibitor-myocarditis: diagnostic and prognostic evidence and limitations","volume":"22","author":"Salem","year":"2025","journal-title":"Curr Heart Fail Rep"},{"issue":"24","key":"10.1016\/j.ejca.2026.116693_bib4","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejca.2026.116693_bib5","article-title":"Cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy \u2013 a real-world observational study","volume":"56","author":"Lerchner","year":"2025","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"15","key":"10.1016\/j.ejca.2026.116693_bib6","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116693_bib7","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2026.116693_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Method"},{"issue":"5","key":"10.1016\/j.ejca.2026.116693_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/diseases12050088","article-title":"Elevated IL-6 and tumor necrosis factor-alpha in immune checkpoint inhibitor myocarditis","volume":"12","author":"Ali","year":"2024","journal-title":"Diseases"},{"issue":"18","key":"10.1016\/j.ejca.2026.116693_bib10","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ejca.2026.116693_bib11","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jcmg.2022.06.014","article-title":"Global circumferential and radial strain among patients with immune checkpoint inhibitor myocarditis","volume":"15","author":"Quinaglia","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.ejca.2026.116693_bib12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116693_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-019-0535-y","article-title":"Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors","volume":"7","author":"Awadalla","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2026.116693_bib14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ejca.2026.116693_bib15","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116693_bib16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1186\/s12885-025-13997-1","article-title":"Immune checkpoint inhibitor-related myocarditis in patients with lung cancer","volume":"25","author":"Cao","year":"2025","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.116693_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaccao.2025.01.020","article-title":"Immune checkpoint inhibitor myocarditis and left ventricular systolic dysfunction","volume":"7","author":"Chen","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejca.2026.116693_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.878211","article-title":"A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer","volume":"9","author":"Faubry","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116693_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.21037\/cdt-24-556","article-title":"Development of peripheral biomarker-based prognostic nomograms for short-term and long-term survival in immune checkpoint inhibitor-associated myocarditis","volume":"15","author":"Guan","year":"2025","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.ejca.2026.116693_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejca.2022.07.018","article-title":"Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: report from an international registry","volume":"177","author":"Nowatzke","year":"2022","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.116693_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.acvd.2022.03.003","article-title":"Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis","volume":"115","author":"Power","year":"2022","journal-title":"Arch Cardiovasc Dis"},{"issue":"10","key":"10.1016\/j.ejca.2026.116693_bib22","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejca.2026.116693_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2024.12.017","article-title":"Characterization of cardiovascular events and prognosis in immune checkpoint inhibitor-related myocarditis","author":"Pereyra Pietri","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2026.116693_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jitc-2021-002553","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116693_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112385","article-title":"Prognosis of immune checkpoint inhibitor-related myocarditis: retrospective experience of a single institution","volume":"136","author":"Qin","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116693_bib26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11739-023-03481-8","article-title":"The role of circulating biomarkers in predicting the 30-day mortality of immune checkpoint inhibitors-related myocarditis: a retrospective cohort study","volume":"19","author":"Zhuang","year":"2024","journal-title":"Intern Emerg Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116693_bib27","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s10637-023-01400-4","article-title":"Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer","volume":"41","author":"Xu","year":"2023","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.ejca.2026.116693_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/cai2.109","article-title":"Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis: a systematic review and meta-analysis","volume":"3","author":"Song","year":"2024","journal-title":"Cancer Innov"},{"issue":"1","key":"10.1016\/j.ejca.2026.116693_bib29","first-page":"53","article-title":"Complementary use of cardiac magnetic resonance and 18 F-FDG positron emission tomography imaging in suspected immune checkpoint inhibitor myocarditis","volume":"10","author":"Tong","year":"2024","journal-title":"Cardiooncology"},{"key":"10.1016\/j.ejca.2026.116693_bib30","article-title":"Multi-organ immune-related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: a multi-center study","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116693_bib31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaccao.2023.09.004","article-title":"Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: contemporary 1-year outcomes","volume":"5","author":"Itzhaki Ben Zadok","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116693_bib32","first-page":"21","article-title":"The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: including myocarditis and the new entity of non inflammatory left ventricular dysfunction","volume":"8","author":"Andres","year":"2022","journal-title":"Cardiooncology"},{"issue":"3","key":"10.1016\/j.ejca.2026.116693_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1148\/radiol.211765","article-title":"Cardiac MRI features and prognostic value in immune checkpoint inhibitor-induced Myocarditis","volume":"303","author":"Cadour","year":"2022","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ejca.2026.116693_bib34","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1148\/radiol.2021210814","article-title":"Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: a prospective study","volume":"301","author":"Faron","year":"2021","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.ejca.2026.116693_bib35","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ehf2.14664","article-title":"Cardiac magnetic resonance-based layer-specific strain in immune checkpoint inhibitor-associated myocarditis","volume":"11","author":"Li","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejca.2026.116693_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2022.110558","article-title":"Applying quantitative CMR parameters for detecting myocardial lesion in immune checkpoint inhibitors-associated myocarditis","volume":"156","author":"Zhao","year":"2022","journal-title":"Eur J Radiol"},{"issue":"11","key":"10.1016\/j.ejca.2026.116693_bib37","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.1007\/s00330-022-08844-x","article-title":"The prognostic value of global myocardium strain by CMR-feature tracking in immune checkpoint inhibitor-associated myocarditis","volume":"32","author":"Zhao","year":"2022","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116693_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: Proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejca.2026.116693_bib39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejca.2026.116693_bib40","article-title":"Triple M overlap syndrome: Myocarditis, myositis and myasthenia gravis after a single administration of pembrolizumab","volume":"17","author":"Baptista","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.ejca.2026.116693_bib41","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","author":"Power","year":"2025","journal-title":"Eur Heart J"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:09:55Z","timestamp":1777622995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"alternative-id":["S0959804926004739"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116693","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116693"}}